Jaguar Health, Inc. — SEC Form D Filing

Jaguar Health, Inc. filed an SEC Form D on June 30, 2026, reporting $40.80M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
June 30, 2026
Amount reported
$40.80M
Round stage
Series B+
Industry
Pharmaceuticals
Website
https://jaguar.health/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People and animals experience gastrointestinal distress, encompassing symptoms like chronic debilitating diarrhea, urgency, and bowel incontinence, for which there is a need for effective treatments. Specifically, cancer therapy can cause related diarrhea, and rare diseases like short bowel syndrome and microvillus inclusion disease also present urgent GI issues.

Solution

Jaguar Health discovers, develops, and commercializes novel plant-based prescription medicines, such as crofelemer, to address various gastrointestinal diseases and conditions. These medicines are in different stages of development, including clinical trials for cancer therapy-related diarrhea and proof-of-concept studies for rare diseases like short bowel syndrome and microvillus inclusion disease.

Verdict

This cleared because investors explicitly bet on the de-risked nature of a late-stage pharmaceutical asset, not on the promise of a novel platform. The capital infusion signaled confidence in crofelemer's path to market approval for specific gastrointestinal indications, anticipating a clear revenue stream from a defined patient population. Upside was limited by the single-asset focus and the high cost of clinical trials, which constrained the ability to broadly capitalize on the "plant-based medicine" narrative.

Source: SEC EDGAR Form D filing